

Katja Seipel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8678536/publications.pdf>

Version: 2024-02-01

15
papers

248
citations

933447

10
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

379
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivation of the p53-“KLF4”-CEBPA Axis in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 746-756.	7.0	40
2	MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. <i>Haematologica</i> , 2018, 103, 1862-1872.	3.5	28
3	Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. <i>Leukemia Research</i> , 2017, 53, 28-34.	0.8	23
4	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. <i>Experimental Hematology</i> , 2020, 88, 7-14.e3.	0.4	21
5	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 170.	3.7	20
6	Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1779.	3.7	20
7	Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 789-796.	1.7	19
8	MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 89, 106296.	0.8	18
9	Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. <i>Cancers</i> , 2022, 14, 2516.	3.7	15
10	sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1463-1471.	2.4	14
11	BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. <i>Cancers</i> , 2021, 13, 581.	3.7	12
12	(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2842.	3.7	6
13	RNA Targeting in Acute Myeloid Leukemia. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1225-1232.	4.9	6
14	Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8092.	4.1	5
15	Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 1188-1197.	1.9	1